This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
4 Aug 2020

Catalent adds potent manufacturing capabilities at its Buenos Aires site

Catalent's facility in Loma Hermosa, Buenos Aires.

The extension will add a capacity of over 10 million doses per annum to the site.

Catalent has announced it plans to expand its Argentinian site in Loma Hermosa, Buenos Aires, which will add more than 11,000 sq. ft of production space and will be segregated and designed to handle cytotoxic and highly active products for prescription softgel manufacturing.

The new facilities, which are due to be completed in December 2021, will include two new manufacturing vessels of 40 and 300 liters, which include an automatic cleaning system and an innovative mixing device suitable for very high viscosity formulations, a capsule filling line and six drying tunnels.

This will add a capacity of over 10 million doses per annum to the site, which supplies products to the Latin American, US and European markets.

“This investment will allow the site to grow and handle a wider range of projects, reacting to the increased demands of the industry for high potency treatments in areas such as oncology,” commented Sergio Alter, Vice President & General Manager Softgel Technologies, Latin America.

He added: “Not only will this increase the capacity of the site, but the design of the new facility will see it meet the highest standards of environmental and energy efficiency.”

Catalent’s 265,000 sq.-ft-facility in Buenos Aires currently houses softgel manufacturing operations, providing customers with a full range of development services, from formulation to packaging.

Mentioned Companies
Catalent Pharma Solutions
View company profile

Related News